8-K: Akari Therapeutics Announces Full-Year 2023 Financial Results and Merger with Peak Bio

Akari Therapeutics reported its full-year 2023 financial results, highlighted by a merger agreement with Peak Bio and advancements in its clinical programs.

Summary

• Akari Therapeutics announced its financial results for the full year 2023, reporting a net loss of approximately $10.0 million, compared to a net loss of $17.7 million in 2022.
• The company's research and development expenses decreased to approximately $5.5 million in 2023 from $9.6 million in 2022.
• General and administrative expenses also decreased to approximately $11.4 million in 2023 from $13.5 million in 2022.
• Akari had approximately $3.8 million in cash as of December 31, 2023, and received an additional $2.0 million in gross proceeds in March 2024.
• The company is planning to secure additional capital in the second quarter of 2024.
• Akari has entered into a definitive merger agreement with Peak Bio in an all-stock transaction, which is expected to expand their pipeline.
• The combined company will continue to trade on the Nasdaq Capital Market as AKTX.
• The company is advancing its Phase 3 clinical trial for nomacopan in pediatric HSCT-TMA, with 10 patients treated in Part A to date.
• Akari is also progressing pre-clinical development of long-acting PAS-nomacopan for geographic atrophy (GA).

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The merger and pipeline advancements are positive, but the low cash balance and ongoing losses temper the overall sentiment. The reduction in expenses and net loss is a positive sign.

Positives

• The merger with Peak Bio is expected to expand the company's pipeline and create new growth opportunities.
• The company's net loss decreased significantly in 2023 compared to 2022.
• Both research and development and general and administrative expenses were reduced in 2023.
• The company has made progress in its Phase 3 clinical trial for nomacopan in pediatric HSCT-TMA.
• The pre-clinical development of PAS-nomacopan for geographic atrophy is advancing with positive results.
• Akari has secured orphan drug designations for nomacopan, which could lead to market exclusivity and a Priority Review Voucher.

Negatives

• The company had only $3.8 million in cash at the end of 2023, requiring additional capital raising.
• The company is still operating at a loss, despite improvements.
• The merger with Peak Bio is subject to closing conditions and may not be completed.

Risks

• The company's clinical development plans are subject to risks and uncertainties, including the possibility of delays or negative results.
• The merger with Peak Bio may not be successful, and the integration of the two companies could be challenging.
• The company's ability to secure additional capital is not guaranteed.
• The company's intellectual property protection may not be adequate.
• The company operates in a dynamic industry and economy, and new risks and uncertainties may emerge.

Future Outlook

Akari plans to complete a strategic assessment of its pipeline, secure additional capital in the second quarter of 2024, and close the merger with Peak Bio. The company will also continue to advance its clinical programs and pre-clinical research.

Management Comments

• Rachelle Jacques, Akari President and CEO, stated that the company advanced its Phase 3 and pre-clinical development programs and paved the way for a merger that will expand the pipeline.
• Management believes they are building strong momentum and are excited about the possibilities for the combined company.

Industry Context

The announcement comes during a challenging economic period for the biotech sector, highlighting the importance of strategic mergers and pipeline expansion for companies like Akari. The focus on rare diseases and unmet medical needs aligns with current industry trends.

Comparison to Industry Standards

• Akari's reduction in operating expenses is a positive sign, as many biotech companies are under pressure to control costs.
• The merger with Peak Bio is a common strategy for smaller biotech companies to gain access to more resources and diversify their pipelines, similar to other recent mergers in the sector.
• The focus on orphan drug designations and rare diseases is a common strategy for biotech companies seeking faster regulatory pathways and market exclusivity, similar to companies like BioMarin and Alexion.
• The development of long-acting therapies like PAS-nomacopan aligns with the industry trend of improving patient convenience and adherence, similar to companies developing extended-release formulations.

Stakeholder Impact

• Shareholders may benefit from the potential growth and value creation opportunities resulting from the merger.
• Employees may experience changes due to the integration of the two companies.
• Patients with HSCT-TMA and geographic atrophy may benefit from the development of new treatment options.
• Creditors may be impacted by the company's financial performance and capital raising activities.

Next Steps

• Complete the strategic assessment of the combined pipeline.
• Secure additional capital in the second quarter of 2024.
• Close the merger with Peak Bio.
• Initiate Part B of the Phase 3 clinical trial for nomacopan in pediatric HSCT-TMA.
• Advance the clinical development of PAS-nomacopan for geographic atrophy.

Key Dates

Keywords

Akari Therapeutics, Peak Bio, Merger, Nomacopan, HSCT-TMA, Geographic Atrophy, PAS-nomacopan, Clinical Trial, Financial Results, Biotechnology, Autoimmune Diseases, Inflammatory Diseases